Clinical Trial Update: A Clinical Trial to Evaluate the Immunogenicity of the Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017 [Phase 4]

View source ↗

Summary

Phase 4 trial assessing immunogenicity of the nonavalent HPV vaccine in men who have sex with men and are HIV-infected.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Nonavalent HPV vaccine (HPV vaccine (nonavalent))

Snippet

Sponsor: Fundacion SEIMC-GESIDA | Conditions: HIV Infections | Phase 4 | Status: COMPLETED